NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
27 Nov 2012

Endosense secures USD 40.3M/CHF 37.4M Series C financing

GENEVA – November 27, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the close of a USD 40.3 million/CHF 37.4 million series C financing.
23 Nov 2012

TiGenix focus on advanced cell therapy programs

Leuven (BELGIUM) – November 23, 2012 – TiGenix (Euronext Brussels: TIG), the European leader in cell therapy, announced today the definitive closure of its biomaterials unit, TiGenix Ltd., to allow the company to fully focus on the further commercial roll-out of ChondroCelect®, and its cell therapy product development pipeline.
Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman<
21 Nov 2012

Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman

Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.
13 Nov 2012

TiGenix signs agreement for commercialization of ChondroCelect in the Middle East

Leuven (Belgium) – November 13, 2012 – TiGenix NV (Euronext Brussels: TIG) and pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab Emirates, today announced that they have signed an exclusive agreement for the commercialization of ChondroCelect® in the Middle East region.
Jon Askaa joins Inbiomotion Board of Directors – Management team strengthened<
08 Nov 2012

Jon Askaa joins Inbiomotion Board of Directors – Management team strengthened

Inbiomotion is a company focused on the development of biomarkers for the prediction of bone metastasis
08 Nov 2012

TiGenix Business Update & Financial Highlights for Q3 of 2012

Leuven (BELGIUM) – November 8, 2012 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the third quarter ending September 30, 2012.
09 Oct 2012

TiGenix announces publication of Cx601 Phase I/IIa study in International Journal of Colorectal Disease

Leuven (BELGIUM) – October 9, 2012 – TiGenix (Euronext Brussels: TIG) announced today the publication in the International Journal of Colorectal Disease of the Phase I/II study of Cx601: Expanded allogeneic adipose-derived stems cells (eASCs) for the  treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase  I/II clinical trial.
25 Sep 2012

TiGenix’s new European production facility obtains EMA approval for commercial production of ChondroCelect

Leuven (BELGIUM) – September 25, 2012 – TiGenix (Euronext Brussels: TIG) announced today that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee, in its new state-of-the-art manufacturing facility in Sittard Geleen (NL).
20 Sep 2012

TiGenix appoints Jean Stéphenne chairman & Russell Greig member of board of directors

Leuven (BELGIUM) – September 20, 2012 – TiGenix (Euronext Brussels: TIG) announcedtoday that the Company has appointed Jean Stéphenne as independent director and new chairman of the Company’s board of directors, and Russell Greig as independent director, in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from the board.
24 Aug 2012

MedLumics Names Prof. Wolfgang Drexler President of its Scientific Advisory Board

MADRID, August 24, 2012 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of world-renowned OCT expert Prof. Wolfgang Drexler as president of the company’s Scientific Advisory Board.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка